$28.25+2.6%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Just reported
From Arcutis Biotherapeutics, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$143.9M
+45% y/y
+11% q/q
Guided
—
No guide given
Actual
$0.06
0.0% y/y
-45% q/q
Guided
—
No guide given
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $143.9M | $99.2M | +45.05% |
| Profit | $8.8M | $7.4M | +18.77% |
| Profit per share | $0.06 | $0.06 | 0.00% |
| Free Cash Flow | $18.8M | -$1.8M | +1,171.89% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Arcutis Biotherapeutics, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Yet another strong quarter of performance reflects the consistent execution of our corporate strategy and further strengthens our financial position. ZORYVE continues to lead the branded non-steroidal topical segment driven by its efficacy and tolerability across multiple inflammatory skin conditions and patient populations. We are very excited to launch a new awareness campaign with Simone Biles, a World Champion gymnast who uses ZORYVE herself, to raise awareness of inflammatory skin diseases and of advanced targeted topicals like ZORYVE,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company that champions meaningful innovation to address the urgent needs of individuals living with immune-mediated dermatological diseases and conditions. With a commitment to solving the most persistent patient challenges in dermatology, Arcutis has a growing portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases. Arcutis’ unique dermatology development platform coupled with our dermatology expertise allows us to develop differentiated therapies against biologically validated targets, and has produced a robust pipeline for a range of inflammatory dermatological conditions.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Arcutis Biotherapeutics, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Actual
$9.4M
+11% y/y
-43% q/q
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.